Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42,200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[No title available]
[No authors listed] [No authors listed] PMID: 36869918
Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: a multicenter study.
Huang C, Zhu XD, Shen YH, Xu B, Wu D, Ji Y, Chen LL, Song TQ, Zhang W, Zeng ZM, Huang HS, Wang K, Huang LQ, Chen YJ, Yang YC, Zhou LD, Long G, Zhao HT, Wang YC, Ge NL, Chen Y, Tan CJ, Zhou J, Fan J, Sun HC. Huang C, et al. Among authors: huang hs, huang lq. BMC Cancer. 2023 May 9;23(1):416. doi: 10.1186/s12885-023-10898-z. BMC Cancer. 2023. PMID: 37158833 Free PMC article.
Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study.
Xu B, Dong SY, Bai XL, Song TQ, Zhang BH, Zhou LD, Chen YJ, Zeng ZM, Wang K, Zhao HT, Lu N, Zhang W, Li XB, Zheng SS, Long G, Yang YC, Huang HS, Huang LQ, Wang YC, Liang F, Zhu XD, Huang C, Shen YH, Zhou J, Zeng MS, Fan J, Rao SX, Sun HC. Xu B, et al. Among authors: huang hs, huang c, huang lq. Liver Cancer. 2022 Nov 28;12(3):262-276. doi: 10.1159/000528034. eCollection 2023 Aug. Liver Cancer. 2022. PMID: 37601982 Free PMC article.
Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma.
Lu JC, Wu LL, Sun YN, Huang XY, Gao C, Guo XJ, Zeng HY, Qu XD, Chen Y, Wu D, Pei YZ, Meng XL, Zheng YM, Liang C, Zhang PF, Cai JB, Ding ZB, Yang GH, Ren N, Huang C, Wang XY, Gao Q, Sun QM, Shi YH, Qiu SJ, Ke AW, Shi GM, Zhou J, Sun YD, Fan J. Lu JC, et al. Among authors: huang xy, huang c. Nat Commun. 2024 Jan 20;15(1):621. doi: 10.1038/s41467-024-44795-1. Nat Commun. 2024. PMID: 38245530 Free PMC article.
42,200 results
You have reached the last available page of results. Please see the User Guide for more information.